We are developing and commercializing precision medicine technologies to support personalized selection of treatment.
We have successfully commercialized the technologies for canine lymphoma, and have successfully developed prototype technologies for the following diseases:
We have developed, patented, and published the technology, namely NDMM-1, capable of predicting each NDMM patient’s response and/or survival following the first-line treatment based on one of the following regimens:
The technology utilizes AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Accordingly, longer survival is expected when an NDMM patient is treated by the therapy to which he or she is low risk to.
We are currently filing approvals for the technology in order to provide our services in South Korea, the U.S., and other countries. We are also developing NDMM-2, which will support personalized optimization of melphalan dosage for transplant eligible NDMM.
Published in npj Precision Oncology, May 2023
ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
We have developed, patented, and are in the process of publishing our new technology for AML. The technology utilizes the patient-derived cancer cells’ sensitivity to 21 anticancer drugs, which enables predictions of the patient's response and/or survival following the treatment by one of the two regimens below:
The technology takes advantage of AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Consequently, longer survival is expected when an AML patient is treated by the therapy to which the patient is low risk to.
We presented our AML technologies at the American Society of Hematology Annual Meeting in 2023, and have filed for approval in South Korea and other countries with the intention of launching our commercial services by 2025.
We have developed, patented, and are in the process of publishing our new technology for NHL. The technology utilizes the patient-derived cancer cells’ sensitivity to 18 anticancer drugs, which enables predictions of the patient's response and/or survival following the standard treatment for the two subtypes:
The technology takes advantage of AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Consequently, longer survival is expected for the low risk subgroup as shown below.
We presented our NHL technologies at the American Society of Hematology Annual Meeting in 2023, and have filed for approval in South Korea and other countries with the intention of launching our commercial services by 2025.
Interested in personalizing treatment plans for cancer patients? Please fill out the form and we will get back to you shortly.
